Skip to main content
Caplight Logo









General Proximity

General Proximity

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.generalproximity.bio/

Last Round

Strategic

Apr 30, 2026

Total Funding Raised

$28M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

General Proximity is a biotechnology company that develops next-generation induced-proximity medicines using its proprietary OmniTAC platform to target previously undruggable proteins.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

targeted protein degradationTPDdrug discoveryOmniTACbiotech platformoncology researchundruggable proteinsinduced proximitycomputational biologyprotein degraderspharma partnershipsdrug discovery platformdegradomicsmolecular glueproteolysis targeting chimeraPROTAC

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

General Proximity Comparables

Compare General Proximity with similar companies based on industry and business-model similarity.

General Proximity comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Plexium
91%
Magnet Biomedicine
88%
SEED Therapeutics
88%

General Proximity Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicApr 30, 2026
SeedJan 3, 2025

Key People

Founding team and executive leadership

Armand Cognetta

Founder And CEO

Founding Team

General Proximity Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 72% MoM, reaching 4.2K.

  • Apr 30, 2026

    Raised capital from Daewoong Pharmaceutical and FreeMind Group.

General Proximity Filings

Explore SEC and related filing metadata, where available.

General Proximity filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about General Proximity's valuation, stock price, and market status.

Is General Proximity a public or private company?

General Proximity is a private company.

What is the current stock price of General Proximity?

General Proximity is a private company with no public stock price. No recent secondary market data is available.

How much is General Proximity worth (valuation)?

Valuation information for General Proximity is not publicly available.

Can I buy General Proximity stock?

General Proximity shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was General Proximity's last funding round?

General Proximity's most recent funding round was Early Funding on May 4, 2026.

Who are the main investors in General Proximity?

Key investors in General Proximity include Felicis Ventures.

Will General Proximity IPO soon?

No public IPO plans have been announced for General Proximity.

How can I track General Proximity secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor General Proximity's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range22
Year Founded2019
Last FundingApr 30, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?